Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
γδ T Cell Immunotherapy for Treatment of Breast Cancer
NCT02418481Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Apr 2015
- Primary completion
- Jun 2016
- Modality
- Whole Cell Cancer Vaccines, Prophylactic Vaccines, Allogeneic CAR-T
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic Vγ9Vδ2 T cell therapy, dendritic cell vaccine + cytokine-induced killer cells in breast cancer, sponsored by Fuda Cancer Hospital. Started Apr 2015; status: completed.
02
Drugs
allogeneic Vγ9Vδ2 T cell therapydendritic cell vaccine + cytokine-induced killer cells
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02418481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418481.